Archive | Biopharmaceuticals

Choppy Week in Healthcare with Drug Pricing Issues Yet Again: Update-2-SELL-OFF

Update-2 10:45a 4/17…XBI down 3.37% to FEB support at $86.  Healthcare issues are spilling over to biotech.Red screen day and all biotechs hit very hard.Drug pricing models are under scrutiny. Update-1…NASDAQ ekes out small gains but large cap biotechs take another hit with IBB down 1% to $109.39. All large caps in the red: REGN […]

Continue Reading 0

Biotech Hits New Highs for 2019:The Trends are Bullish…Update-3 at Sell-Off

4/11 ALERT: Need to check out reasons for biotech sell-off; could be proposed drug pricing bills and “affordability board.”  See STAT News . See 4/11 chart below for XBI. Choppy pattern returns at resistance with no breakthrough highs. Biopharma stocks broadly down on. “Red Screen Day”. 4/11/19 12:15p EDT. Update -2…Healthcare and biotech sector weak […]

Continue Reading 0

High Volatility Among Individual stocks with Few Trends…Update-4

Update-4.  4/3 11:45A… Mid and Small Cap biotechs are momentum leaders: XBI hits 2019 high at $92.50. Update-3    4/2/19… Biotechs Outperform Major Market Indices Gene therapy stocks rally big: SGMO 28.96%, VYGR 7.38%, CRSP 6.91%  NTLA 4.9% MGTX up 4.6%, etc. Most Mid-Caps green: BPMC up 2.2%, SRPT up 3.88%, AGIO up 3.41% etc. […]

Continue Reading 0

Biotech Green Screen: Sketchy Recovery is Underway…Update-3

Update-3…3/29 1:15p  EDT. Biotech stocks catching bids today after a choppy week of trading. We will recap our top small cap picks from the JPM Conference after the close: AMRN, GNMK and TDOC. BIIB up again to 237.  CELG up over 7% as prospects for BMY deal look good. ====== Update -2… 3/27. Choppy trendless […]

Continue Reading 0

Biopharma Stocks Rally and Gene Therapy Stocks Are Still Hot (Not?)…Update-2

Update -2 March 24…Concerns about global growth, an inverted TSY yield curve and the German 10 year bond yield dropping below 10% triggered a major sell-off on Friday.The Russell 2000 dropped 3.62%. and the XBI dropped 4.62%. For the week ending 3/22: the XBI was down 4.3%, IBB down 5.3%, FBT down 3.8%. The XLV […]

Continue Reading 0

Biotech Stocks catch a Second Wind Helped by Tech Stocks…Update-4

ALERT 3/21/19…BIOGEN (BIIB) down 28% to $233 after dropping Alzheimer’s Disease late stage trial; another failed clinical stage drug in AD. (more later). IBB down 2.5%. ====== 3/20/19…a whipsaw day…Powell comes to market rescue with “economy is growing at a solid pace” and leaving rates unchanged (patience); but Trump says earlier that he will keep […]

Continue Reading 0

Sideways Market Vexes Traders: Biotech Stocks are Fading…Updates-3 Rally Time!

Update-3…3/11…Gene Therapy stocks go green screen! Big 5% winners: VYGR NTLA BLUE EDIT See complete list below (paste list into yahoo finance for tracking) Update-2…3/11…Market gets support from 60 Minutes-Powell comments and Gene Therapy; NASDAQ up 1.77%; XBI up 1.74% to $87.94  as of 1:15p Update-1… 3/10…Friday’s Comeback needs some follow through with small caps: […]

Continue Reading 0

Biotech Sell-Off: Momentum Eases on Profit Taking and Geopolitical Uncertainty…Update-2 Gene Therapy

Update-2…Biotech rally Friday and Gene Therapy stocks One clue to the stealth rally on Friday is this article in Barron’s published Saturday (? hmmm) Why Big Pharma is Diving into Gene Therapy If you cannot access this article and are not a subscriber go plunk down $5 as there is other good stuff on the […]

Continue Reading 0

Small Cap Biotechs Lead the Market in 2019 Up 20% YTD…GNMK, ONCE, XBI-Updates

Update: 1:40 EST 2/25… Gene Therapy stocks soar on Spark (ONCE) Deal: BLUE, CRSP, RARE; and XBI up 4.2%. Another big deal as GE sells healthcare business to Danher (DHR) for $21.4B; GE up 8.26%, DHR up 8.38%. ========== M&A Drives Mid and Small Cap Biotechs Stocks Higher The Small Cap weighted XBI is up […]

Continue Reading 0

J.P.Morgan Healthcare Conference: Picks and Trades… Updates GNMK

Update: GenMark (GNMK) Soars on Q4 and Full Year 2018 Results Revenues of $70.8M were 35% over 2017 Results Q4 Revenues were $19.4M an increase of 21% over prior year. ePlex Revenues for Q4 were 412.1M an increase of 110% over prior year. Loss per share was reduced from 26c per share to 21c per […]

Continue Reading 0